Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Oct 9, 2026 - P2 | N=36 | Recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Mar 2027 ➔ Aug 2029 | Trial primary completion date: Mar 2027 ➔ Aug 2029
Trial completion date • Trial primary completion date • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Indolent Lymphoma • Large B Cell Lymphoma • Leukemia • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • CD20
|